 Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes.Several trials have been terminated due to serious cardiovascular toxicity.Ethyl 2-(methylamino)benzoate is condensed with ethyl malonate.